Mer­ck, Ei­sai notch full ap­proval for Keytru­da-TKI in­hibitor com­bo in ad­vanced en­dome­tri­al can­cer

Mer­ck PD-1 in­hibitor Keytru­da has been in the hot seat as the FDA ri­fles through its ac­cel­er­at­ed ap­proval pro­gram for drugs that even­tu­al­ly flop con­fir­ma­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.